Haemonetics (HAE) Return on Equity ROE from the first quarter 2026 to first quarter 2026 and annually, average high and low, overall ranking from Jun 27 2026 to Jun 28 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Haemonetics Corporation  (NYSE: HAE)

Haemonetics's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Haemonetics in the first quarter 2026?
Haemonetics Corporation achieved a return on average equity (ROE) of 11.66 % in its first quarter 2026, this is above HAE's average return on equity of 7.63%.
Haemonetics Corporation shareholder's equity over the 12 months ending in its first quarter 2026 are valued at $826 million

ROE has advanced compared to 11.62% in the fourth quarter 2026, due to net income growth.

Within the Medical Equipment & Supplies industry 31 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 1225, from total ROE ranking in the fourth quarter 2026 at 1262.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 27 2026)
I. Quarter		 (Mar 28 2026)
IV. Quarter		 (Dec 27 2025)
III. Quarter		 (Sep 27 2025)
II. Quarter		 (Jun 28 2025)
I. Quarter
Y / Y Equity Change -5.12 % -2.99 % -14.49 % -3.38 % -
Y / Y Net Income Change -3 % - 19.33 % 14.34 % -11.32 %
Net Income (TTM) in Millions 96 97 175 168 163
Return On Equity (TTM) 11.66 % 11.62 % 20.8 % 19.15 % 18.45 %
HAE's Total Ranking # 1225 # 1262 # 113 # 562 # 579
Equity (TTM) in Millions 837 796 821 849 882
Seq. Equity Change 5.12 % -2.99 % -3.34 % -3.75 % 7.49 %
Seq. Net Income Change - - 15.66 % 13.67 % -41.31 %

Back to HAE Management Effectiveness >> HAE's 5 Years Annual ROE >> Compare HAE ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 32
Sector # 128
Overall # 1225

Return On Equity Statistics
High Average Low
20.8 %
7.63 %
-8.64 %
(Dec 27 2025)   (Jul 02 2016)





HAE Annual Return On Equity (Mar 28 2026)
2026		 (Mar 29 2025)
2025		 (Mar 30 2024)
2024		 (Apr 01 2023)
2023		 (Apr 02 2022)
2022
Total Equity in Millions 796 821 960 818 749
Y / Y Equity Change -2.99 % -14.49 % 17.35 % 9.15 % 2.43 %
Net Income in Millions 97 168 118 115 43
Y / Y Net Income Change -41.97 % 42.64 % 1.87 % 166.05 % -45.42 %
Return On Equity 12.22 % 20.43 % 12.25 % 14.11 % 5.79 %

Back to HAE Management Effectiveness >> HAE's 5 Years Annual ROE >> Compare HAE ROE to its Competitors




Annual Roe Comment
In 2026 ROE decreased compared to the previous year to 12.22 %, due to deterioration of net income.


More Return On Equity Ratios
Medical Equipment & Supplies Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
HAE's' Return on Equity at Yahoo Finance
HAE's Roe Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for HAE's Competitors
Subscribers only: Roe for Haemonetics's Suppliers
Subscribers only: Return On Equity for HAE's Customers




Companies with similar Return On Equity at Jun 27 2026, within Healthcare Sector ROE
Pro dex Inc   31.96 %
Protalix Biotherapeutics inc   31.61 %
Illumina Inc   31.08 %
Innoviva Inc   30.03 %
Phibro Animal Health Corporation  29.66 %
Chemed Corporation  29.45 %
Solventum Corporation  28.96 %
Pacs Group Inc   27.00 %
Sotera Health Company  26.75 %
Insulet Corporation  26.69 %
Bioventus Inc   25.96 %
Johnson and Johnson  25.74 %
Encompass Health Corporation  25.52 %
Resmed Inc   24.21 %
Healthcare Services Group Inc   24.12 %
Electromed Inc   23.65 %
Iradimed Corporation  23.45 %
Vertex Pharmaceuticals Inc  23.31 %
Lantheus Holdings Inc   23.27 %
Msa Safety Inc  23.15 %
Prestige Consumer Healthcare Inc   21.77 %
Jazz Pharmaceuticals Plc  21.37 %
Neurocrine Biosciences Inc   21.13 %
Universal Health Services Inc   20.89 %
Puma Biotechnology Inc   20.85 %
Entera Bio Ltd   20.82 %
United Therapeutics Corporation  20.18 %
Ligand Pharmaceuticals Incorporated  20.06 %
Harmony Biosciences Holdings inc   20.06 %
Pediatrix Medical Group Inc   19.89 %

Date modified: 2026-09-05T15:12:04+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.